Definitive Contract 75N91019C00021

The Department of Health and Human Services National Institutes of Health National Center for Advancing Translational Sciences awarded a Small Business Innovation Research (SBIR) Phase I contract to Gencirq, Inc., a for-profit organization, to develop a screening platform for therapeutics using a genetic lysis circuit. The firm-fixed-price contract has a potential value of $225,000.00 and a completion date of October 31, 2020. The contract was set aside for small businesses and is associated...

This SBIR Phase I contract was awarded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH) within the Department of Health and Human Services (HHS), to Zymeron Corporation, a Minority Owned Small Business. The $349,790 Firm Fixed Price contract supports research and development of "Targeted and Sustained Release Microparticles for Colon Cancer Chemoprevention." This work is part of the NIH/CDC SBIR Program, which aims to stimulate technological...

This is a $268,641 Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Symberix, Inc., a small business located in Durham, North Carolina. The contract is for the development of targeted cancer therapies that modulate the intestinal microbiome, under SBIR Topic 351. Symberix, Inc. is an early-stage spin-out from the University of North Carolina that is focused on developing symbiotic...

<p>This is a $299,999.00 Firm Fixed Price contract awarded by the National Cancer Institute, a civilian agency, to Innogenomics Technologies, L.L.C., a minority-owned small business, under the Small Business Innovation Research (SBIR) Program Phase I. The contract is for research and development in the area of biomedical (basic research). It was awarded on September 22, 2015 with a final completion date of March 21, 2017. The contract has a total small business set-aside designation.</p>

Gencirq, Inc. was awarded a $1,499,584.99 firm fixed price definitive contract by the National Institutes of Health's National Center for Advancing Translational Sciences under the Small Business Innovation Research Program Phase II. The contract is for the development of a bacterial synchronized lysis circuit platform to deliver therapeutics, with work to be performed in Santa Barbara, California through May 2023. The award is designated as a total small business set aside. No major...

This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian federal agency, to Mediomics LLC, a woman-owned small business. The contract is for the development of glycosylation-specific research under SBIR Topic 294, with a ceiling value of $148,569. SBIR contracts are set-aside for small businesses to engage in research and development for the government. This Phase I contract represents the initial research and feasibility...

This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian federal agency, to Mediomics LLC, a woman-owned small business. The contract, valued at $185,116, is a firm-fixed-price definitive contract for research and development work. The contract was awarded on September 24, 2010 and has an ultimate completion date of June 23, 2011. As an SBIR Phase I contract, it is focused on the early-stage feasibility study of a...

This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), part of the Department of Health and Human Services (DHHS), to Theranano LLC, a small disadvantaged, woman-owned business. The $300,000 fixed-price contract is for research on the sustained delivery of PARP inhibitors for cancer chemoprevention. This SBIR contract was issued under the DHHS/NIH/CDC SBIR Contract Solicitation PHS 2018-1, which sought proposals from small...

The National Cancer Institute awarded a $455,000 firm fixed-price contract to Oncobiomix Inc., a small business located in San Antonio, Texas, under the Small Business Innovation Research (SBIR) Program Phase I. The award, issued on September 11, 2024, supports research and development of OnCobiomix, a microbiome-based diagnostic test designed to assess prostate cancer risk. As a Phase I SBIR award, this contract represents an initial feasibility and proof-of-concept stage, with a completion...

This $399,987 Small Business Innovation Research (SBIR) Phase I contract was awarded by the National Cancer Institute (NCI), a part of the National Institutes of Health (NIH), to Care Progress LLC, a small business limited liability company. The contract supports the development of cancer clinical trials recruitment and retention tools for participant engagement, as described in the original SBIR solicitation. The solicitation sought proposals for SBIR Phase I and Phase II contracts to conduct...